Intra-Cellular Therapies Inc. diskutieren
Intra-Cellular Therapies Inc.
WKN: A1XDTL / Symbol: ITCI / Name: ITI / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
123,00 €
0,82 %
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $92.00 price target on the stock, up previously from $68.00.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $130.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Royal Bank of Canada from $106.00 to $108.00. They now have an "outperform" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Morgan Stanley from $92.00 to $95.00. They now have an "overweight" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $100.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at JPMorgan Chase & Co. from $81.00 to $89.00. They now have an "overweight" rating on the stock.
Ratings data for ITCI provided by MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) was upgraded by analysts at Cantor Fitzgerald from a "hold" rating to a "strong-buy" rating.
Ratings data for ITCI provided by MarketBeat
Neueste Beiträge
StockNews_com in Addus Homecare Corp. diskutieren